Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures



    VANCOUVER, Aug. 4 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP) today announced the launch of a series of new, proprietary Quill(TM)
SRS product codes specifically designed for laparoscopic, or minimally
invasive, gynecology procedures, including hysterectomies and myomectomies. In
2008, there were approximately 750,000 hysterectomies performed in the United
States of which approximately 130,000 were performed laparoscopically. In
addition, there were approximately 72,000 myomectomies performed in the United
States to remove uterine fibroid tumors. Management estimates 6-8% annual
growth in laparoscopically assisted hysterectomies through 2014.
    Angiotech's proprietary Quill SRS barbed suture technology offers
significant advantages in laparoscopic surgery whether performed manually by
surgeons or through robotic assistance. The primary advantage of Quill SRS for
laparoscopic procedures is the ability to close a wound using Quill without
the surgeon having to tie knots. The exercise of tying knots can be very
challenging and time consuming when surgeons are relegated to operating in a
smaller surgical field as a result of electing to use a minimally invasive
approach for the procedure. A second advantage is to minimize or eliminate the
need for a third hand to maintain tension on the suture as typically required
with a traditional suturing technique in order to deal with tissue recoil. A
third advantage of Quill SRS is that the even distribution of tension and its
ability to maintain the tension along the length of the suture also provides
hemostatic benefits, often eliminating or minimizing the need for standard
hemostatic sutures.
    These and other novel elements of Angiotech's Quill SRS for laparoscopic
and robotic-assisted surgery are expected to significantly reduce the time and
difficulty of completing a wound closure in these types of surgical
procedures, where tying sutures through small incisions using instruments,
while having limited visibility of patient anatomy, can be one of the most
difficult and tedious aspects of such procedures for physicians. Patients may
also benefit through reduced surgical times, and therefore reduced time under
anesthesia, and health care facilities and payors may also benefit from the
potential to reduce operating room time needed, or the total cost of material
needed, to complete such surgical procedures.
    Angiotech's new Quill SRS product codes for laparoscopic gynecology
procedures are available in our polydioxanone (PDO) suture material in size
-0- with 7 cm by 7 cm and 14 cm by 14 cm lengths, and include our newly
designed 36 mm needles.
    The use of Quill SRS in laparoscopic gynecology surgery was first
reported by James Greenberg, MD, and Jon Einarsson, MD, MPH, of the Centre for
Women's Surgery at Brigham & Women's/Faulkner Hospitals and Harvard Medical
School Boston, Massachusetts in the Journal of Minimally Invasive Gynecology,
in November of 2008. The results of this small feasibility study looked at the
application of Quill SRS in myomectomy and total laparoscopic hysterectomy
vaginal cuff closures. This publication was then followed by up by a podium
presentation at the American Association of Gynecologic Laparoscopists (AAGL)
annual meeting in the fall of 2008 confirming that there were no post
operative issues or complications from the use of Quill SRS in a patient
series that had grown to 150 patients reviewed to that date. "Bidirectional
barbed sutures greatly facilitate laparoscopic suturing. Further evolution and
incorporation of this suture material into clinical practice seems
inevitable," said Dr. Einarsson.
    "Quill SRS helps surgeons overcome one of the largest obstacles in
advanced minimally invasive surgery - tying knots laparoscopically. With this
revolutionary technology, we should anticipate the introduction of the next
generation of safer minimally invasive procedures," said Dr. Greenberg.
    For more information about Quill SRS for laparoscopic gynecology
procedures, please refer to our Quill SRS website located at
www.angioedupro.com and view our online movies demonstrating Quill SRS in use.
All Quill SRS products are also available for purchase online by accredited
surgeons at Angiotech's e-commerce site which can be accessed at
https://ecommerce.angiotech.com/Main/Home.aspx.

    About the Quill(TM) Self-Retaining System (SRS)

    The Quill SRS product line represents a revolutionary technology in wound
closure made possible by bidirectional fixation within the wound. Its patented
design allows the surgeon to begin closure at the midpoint of the wound and
suture in two directions from the midpoint. Barbs within the Quill SRS product
distribute tension across the wound and eliminate the need for knots.

    
    Forward Looking Statements
    --------------------------
    

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for 2009 and beyond, our strategies
or future actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research, development, product
and drug development. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are taken into
account as part of our assumptions underlying these forward-looking statements
and include, among others, the following: general economic and business
conditions, both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing products or our
ability to develop and commercialize future products; competition; existing
governmental regulations and changes in, or the failure to comply with,
governmental regulations; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products sold by our partners;
decisions, and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the requirement for
substantial funding to conduct research and development and to expand
manufacturing and commercialization activities or consummate acquisitions; and
any other factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual results expressed
or implied by the forward-looking statements in this press release to differ
materially from our actual results. These operating risks include: our ability
to attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting from third
party challenges to our patents; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; and any other factors referenced in our
other filings with the Securities and Exchange Commission ("SEC") and
applicable Canadian regulatory authorities. For a more thorough discussion of
the risks associated with our business, see the "Risk Factors" section in our
annual report for the year ended December 31, 2008 filed with the SEC on Form
10-K, and our quarterly report for the three months ended March 31, 2009 filed
with the SEC on Form 10-Q.
    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this press release to reflect future
results, events or developments.

    About Angiotech Pharmaceuticals

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at www.angiotech.com.





For further information:

For further information: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,
dede.sheel@fdashtonpartners.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890